Kistler-Tiffany Companies’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Kistler-Tiffany Companies’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-400	Closed	-$17K	–	690
2020 Q3	$17K	Hold	400	–	–	0.01%	412
2020 Q2	$19K	Hold	400	–	–	0.01%	369
2020 Q1	$50K	Hold	400	–	–	0.02%	258
2019 Q4	$50K	Buy	400 +100	+33%	+$8.95K	0.02%	263
2019 Q3	$20K	Hold	300	–	–	0.01%	367
2019 Q2	$24K	Hold	300	–	–	0.01%	336
2019 Q1	$34K	Buy	300 +100	+50%	+$10.9K	0.01%	288
2018 Q4	$20K	Buy	+200	New	+$20.7K	0.01%	324

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Kistler-Tiffany Companies's ICPT Position: Q4 2020 in Review

Kistler-Tiffany Companies sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 400 shares — an estimated $17K sold.

Kistler-Tiffany Companies first reported a position in ICPT in Q4 2018 and held it in 8 quarters. The position peaked at $50K in Q1 2020. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

Kistler-Tiffany Companies reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Kistler-Tiffany Companies sold 400 Intercept Pharmaceuticals, Inc. shares in Q4 2020, an estimated $17K.
Kistler-Tiffany Companies first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2018 and held it in 8 quarters.
Kistler-Tiffany Companies's Intercept Pharmaceuticals, Inc. position peaked at $50K in Q1 2020.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Kistler-Tiffany Companies's 13F filing for Q4 2020, filed 3 Feb 2021.